Along with the technology innovation and evolution, Grove’s clinical results have made continuous progress. To date, over 300 diabetic volunteers have donated their time, effort, and blood to helping Grove develop the world's first noninvasive glucometer. With a clinical research staff of 9 individuals, Grove conducts 40 in-house clinical sessions - 1,000 data pairs (Grove device vs. gold standard blood glucose determination) each week.

The results of Grove's clinical testing are unprecedented for a noninvasive device. The current international standard (ISO 15197) requires point of care glucose meters to vary from the blood standard by less than 20%. Grove’s MARD (mean average relative difference) has exceeded this standard (MARD 8-12%) for more than 2 years. The Company expects that soon a Grove device will be the world’s first-ever noninvasive glucometer to exceed all requirements of the ISO standard.